Full Text | PDF

Theranostics 2017; 7(7):2065-2066. doi:10.7150/thno.20622 This issue Cite

Editorial

In Molecular Pursuit of Bone Metastasis by Fluciclovine PET

Liza Lindenberg^{1,2 ✉}

1. Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
2. Adjunct Assistant Professor of Radiology/Assistant Professor of Medicine, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD

✉ Corresponding author: NIH, Bldg 10 Rm B3B402, MS1088, 10 Center Drive, Bethesda, MD 20892. Phone: 301-443-0604; Fax: 301-480-1434; E-mail: liza.lindenberggov

Abstract

Diagnosing bone metastases with traditional anatomic modalities, such as MRI and CT, is limited by sensitivity, and conventional bone radiotracers are only indirect markers of cancer activity. Fortunately, molecular imaging is uniquely capable of providing radiotracers such as fluciclovine and radiolabeled choline, that actually target tumors in the bone. The merits of research in imaging osseous metastases in animal models using these radiotracers and the implications for future clinical translation are discussed.

Citation styles

©2024 Ivyspring International Publisher. Terms of use